Estás en: / Inicio / Investigaciones / A Randomized, Phase 3, Double-Masked, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of ALT-L9 Versus Eylea® in Patients With Neovascular Age-Related Macular Degeneration

ACTUALIDAD

A Randomized, Phase 3, Double-Masked, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of ALT-L9 Versus Eylea® in Patients With Neovascular Age-Related Macular Degeneration

01/08/2023

INVESTIGADOR:

Dr. Álvaro Fernández-Vega Sanz
ACTIVO

A Randomized, Phase 3, Double-Masked, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of ALT-L9 Versus Eylea® in Patients With Neovascular Age-Related Macular Degeneration

PATOLOGÍA: Degeneración Macular Asociada a la Edad

TRATAMIENTO: ALT-L9

PROMOTOR: Altos Biologics Inc.

Codigo del estudio: ALT-L9-03

By Fernandez Vega

A Randomized, Phase 3, Double-Masked, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of ALT-L9 Versus Eylea® in Patients With Neovascular Age-Related Macular Degeneration

INVESTIGADOR:

PATOLOGÍA: Degeneración Macular Asociada a la Edad

TRATAMIENTO: ALT-L9

PROMOTOR: Altos Biologics Inc.

Codigo del estudio: ALT-L9-03

PÍDENOS CITA AHORA

Déjanos tus datos

LLÁMANOS POR TELÉFONO

ESTAMOS EN

OVIEDO

MADRID